Pharmacoeconomic review report Adalimumab (Humira)
Adalimumab (Humira) is an anti-℗tumour necrosis factor alpha (TNF alpha), available as a syringe of 40 mg/0.8 mL solution for subcutaneous injection at a unit price of 40.36 per syringe. The current review of adalimumab is for the treatment of adult patients with moderately to severely active ulcer...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2016.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820270906719 |
| Sumario: | Adalimumab (Humira) is an anti-℗tumour necrosis factor alpha (TNF alpha), available as a syringe of 40 mg/0.8 mL solution for subcutaneous injection at a unit price of 40.36 per syringe. The current review of adalimumab is for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids, azathioprine and/or 6-Amercaptopurine (6-℗MP), or who are intolerant to such therapies. |
|---|---|
| Descripción Física: | 1 online resource (viii, 39 pages) |
